BACKGROUND AND PURPOSE: The human organic anion transporting polypeptide 1A2 (OATP1A2) is expressed in cells from several regions of the human body, including the kidney, cholangiocytes and the blood-brain barrier, and mediates the cellular flux of various anionic substances, including drugs in clinical use. Several related mammalian transporters have been shown to be subject to post-translational regulation, including kinase-induced internalization. In the present study the role of protein kinase C (PKC) in the regulation of OATP1A2 was investigated in an in vitro cell model. EXPERIMENTAL APPROACH: COS-7 cells in which OATP1A2 was overexpressed were treated with the PKC-specific activator (phorbol 12-myristate 13-acetate; PMA) and the PKC-specific inhibitor (Go6976). The impact of these treatments on the function and regulation of OATP1A2 was determined. KEY RESULTS: PKC activation decreased the transport function of OATP1A2 in a time- and concentration-dependent manner. PMA (0.1 µM) decreased the V(max) of oestrone-3-sulphate uptake and decreased the cell surface expression of OATP1A2 immunoreactive protein; these effects of PMA were prevented by the PKC specific inhibitor Go6976. In further studies, PMA treatment accelerated the internalization of OATP1A2 but did not affect its recycling. The disruption of clathrine-dependent endocytosis attenuated both the constitutive and PKC-modulated internalization of OATP1A2. In contrast, blocking the caveolin-dependent pathway was without effect. CONCLUSIONS AND IMPLICATIONS: PKC regulates the transport function of OATP1A2 by modulating protein internalization; this effect of PKC is mediated in part by clathrine-dependent pathways.
BACKGROUND AND PURPOSE: The humanorganic anion transporting polypeptide 1A2 (OATP1A2) is expressed in cells from several regions of the human body, including the kidney, cholangiocytes and the blood-brain barrier, and mediates the cellular flux of various anionic substances, including drugs in clinical use. Several related mammalian transporters have been shown to be subject to post-translational regulation, including kinase-induced internalization. In the present study the role of protein kinase C (PKC) in the regulation of OATP1A2 was investigated in an in vitro cell model. EXPERIMENTAL APPROACH: COS-7 cells in which OATP1A2 was overexpressed were treated with the PKC-specific activator (phorbol 12-myristate 13-acetate; PMA) and the PKC-specific inhibitor (Go6976). The impact of these treatments on the function and regulation of OATP1A2 was determined. KEY RESULTS:PKC activation decreased the transport function of OATP1A2 in a time- and concentration-dependent manner. PMA (0.1 µM) decreased the V(max) of oestrone-3-sulphate uptake and decreased the cell surface expression of OATP1A2 immunoreactive protein; these effects of PMA were prevented by the PKC specific inhibitor Go6976. In further studies, PMA treatment accelerated the internalization of OATP1A2 but did not affect its recycling. The disruption of clathrine-dependent endocytosis attenuated both the constitutive and PKC-modulated internalization of OATP1A2. In contrast, blocking the caveolin-dependent pathway was without effect. CONCLUSIONS AND IMPLICATIONS: PKC regulates the transport function of OATP1A2 by modulating protein internalization; this effect of PKC is mediated in part by clathrine-dependent pathways.
Authors: H Glaeser; D G Bailey; G K Dresser; J C Gregor; U I Schwarz; J S McGrath; E Jolicoeur; W Lee; B F Leake; R G Tirona; R B Kim Journal: Clin Pharmacol Ther Date: 2007-01-10 Impact factor: 6.875
Authors: Ilaria Badagnani; Richard A Castro; Travis R Taylor; Claire M Brett; Conrad C Huang; Douglas Stryke; Michiko Kawamoto; Susan J Johns; Thomas E Ferrin; Elaine J Carlson; Esteban G Burchard; Kathleen M Giacomini Journal: J Pharmacol Exp Ther Date: 2006-05-15 Impact factor: 4.030
Authors: Henriette E Meyer zu Schwabedissen; Rommel G Tirona; Cindy S Yip; Richard H Ho; Richard B Kim Journal: Cancer Res Date: 2008-11-15 Impact factor: 12.701
Authors: Brandon P Lucke-Wold; Ryan C Turner; Aric F Logsdon; James W Simpkins; Daniel L Alkon; Kelly E Smith; Yi-Wen Chen; Zhenjun Tan; Jason D Huber; Charles L Rosen Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: Svetlana M Stamatovic; Allison M Johnson; Nikola Sladojevic; Richard F Keep; Anuska V Andjelkovic Journal: Ann N Y Acad Sci Date: 2017-04-17 Impact factor: 5.691